microdose glp 1 benefits GLP-1 – näky There isn't enough data to

DPP-4 inhibitors in clinical use today exhibit little or no binding to either DPP-8 or DPP-9

Diabetes Obes Metab (2018) 20(2):46873

Microdosing is an off-label use of GLP-1 medications and is not FDA-approved for the indications discussed herein

These previously unrecognized antidiabetogenic actions of GLP-1m may have therapeutic usefulness

Signaling events leading to the stimulation of Gcg expression in -cells include heterodimerization of the transcription factor paired box protein 6 (Pax6) with cellular muscular aponeurotic fibrosarcoma (c-Maf), MAF bZIP transcription factor B (MafB) or caudal type homeobox 2/3 (Cdx2/3), and consequent binding of these heterodimers to the G1 element (Figure 2) [98,[104], [105], [106]]

J Cereb